Infectious Disease · Pneumocystis jirovecii pneumonia
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Pneumocystis jirovecii pneumonia (PJP) is the most common AIDS-defining opportunistic infection in patients with a CD4 count < 200 cells/mm³.
Patients typically present with an insidious onset of progressive exertional dyspnea, non-productive cough, and fever.
Chest X-ray classically demonstrates bilateral diffuse interstitial infiltrates, though it may appear normal in early disease.
Arterial blood gas (ABG) analysis often reveals an increased alveolar-arterial (A-a) oxygen gradient and hypoxemia.
Elevated serum lactate dehydrogenase (LDH) is a highly sensitive but non-specific marker for PJP in the setting of HIV.
Definitive diagnosis requires visualization of the organism via silver stain or direct fluorescent antibody (DFA) testing of induced sputum or bronchoalveolar lavage (BAL) fluid.
Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line treatment, with adjunctive corticosteroids indicated if the arterial oxygen tension (PaO2) is < 70 mmHg or the A-a gradient is ≥ 35 mmHg.
Vignette unlocked
A 34-year-old male with a history of untreated HIV presents to the clinic with a 3-week history of progressive shortness of breath and a dry, hacking cough. He reports a low-grade fever and significant fatigue. Physical examination reveals tachypnea and bilateral crackles on lung auscultation. His CD4 count is 85 cells/mm³. A chest X-ray shows bilateral perihilar interstitial infiltrates.
What is the most appropriate adjunctive therapy to initiate alongside antimicrobial treatment in this patient?
Corticosteroids
This patient presents with classic signs of PJP; adjunctive corticosteroids are indicated to prevent respiratory failure caused by the inflammatory response to dying organisms when the A-a gradient is elevated.
Full handout
High yield triage
Etiology / Epidemiology
Pneumocystis jirovecii pneumonia (PJP) is the most common AIDS-defining illness in patients with CD4 count < 200 cells/µL.
Clinical Manifestations
Classic presentation is an insidious onset of exertional dyspnea, non-productive cough, and ground-glass opacities on imaging.
Diagnosis
Diagnosis is confirmed via bronchoalveolar lavage (BAL) with silver stain; LDH > 500 U/L is a classic marker.
Treatment
Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line treatment; add corticosteroids if PaO2 < 70 mmHg.
Prognosis
Untreated PJP has a near 100% mortality rate; prophylaxis is mandatory until CD4 count remains > 200 for 3 months.
Full handout
Epidemiology & Etiology
PJP is caused by the fungus Pneumocystis jirovecii, which is ubiquitous in the environment. It primarily affects immunocompromised hosts, specifically those with CD4 < 200 or those on chronic immunosuppressive therapy. It remains the most frequent opportunistic infection in patients with undiagnosed HIV.
Pertinent Anatomy
The organism targets the alveolar spaces, leading to diffuse interstitial inflammation. This impairs gas exchange at the alveolar-capillary membrane, resulting in profound hypoxemia disproportionate to physical exam findings.
Pathophysiology
Inhalation of the organism leads to colonization in the lungs. In the absence of T-cell mediated immunity, the organism proliferates, causing alveolar filling with foamy, proteinaceous exudate. This triggers a massive inflammatory response, leading to hypoxemic respiratory failure and potential pneumothorax formation.
Clinical Manifestations
Patients present with a triad of fever, non-productive cough, and progressive dyspnea. Physical exam is often disproportionately normal despite severe hypoxia. Sudden onset of pleuritic chest pain should raise immediate suspicion for a spontaneous pneumothorax, a known complication of cystic lung disease.
Diagnosis
The gold standard for diagnosis is identification of the organism via bronchoalveolar lavage (BAL) using Gomori methenamine silver stain. Chest X-ray typically shows bilateral, diffuse ground-glass opacities. Serum LDH > 500 U/L is a non-specific but highly sensitive marker for severity.
Treatment
The first-line treatment is Trimethoprim-sulfamethoxazole (TMP-SMX). If the patient is hypoxic (PaO2 < 70 mmHg or A-a gradient > 35 mmHg), adjunctive corticosteroids must be administered to prevent respiratory deterioration. Severe sulfa allergy necessitates switching to pentamidine or atovaquone.
Prognosis
Without treatment, mortality is extremely high. Primary prophylaxis with TMP-SMX is indicated for all patients with CD4 < 200. Patients must be monitored for bone marrow suppression and hyperkalemia during prolonged therapy.
Differential Diagnosis
Bacterial pneumonia: typically presents with lobar consolidation and productive cough
Tuberculosis: often presents with cavitary lesions and night sweats
Cytomegalovirus pneumonia: usually associated with multi-organ involvement
Histoplasmosis: endemic exposure history with hilar lymphadenopathy
Kaposi sarcoma: pulmonary involvement usually presents with nodular lesions